drugset / Trial / NCT02614742
SFX-01 After Subarachnoid Haemorrhage
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SFX-01 in Subarachnoid Haemorrhage, with exploratory evaluations of efficacy.
Timeline
- Start
- 2016-04
- Primary completion
- 2019-09
- Completion
- 2019-11
Publications
- Zolnourian A, Garland P, Holton P, Arora M, Rhodes J, Uff C, Birch T, Howat D, Franklin S, Galea I, Bulters D. A Randomised Controlled Trial of SFX-01 After Subarachnoid Haemorrhage - The SAS Study. Transl Stroke Res. 2025 Aug;16(4):1031-1043. doi: 10.1007/s12975-024-01278-1. Epub 2024 Jul 19.
- Zolnourian AH, Franklin S, Galea I, Bulters DO. Study protocol for SFX-01 after subarachnoid haemorrhage (SAS): a multicentre randomised double-blinded, placebo controlled trial. BMJ Open. 2020 Mar 25;10(3):e028514. doi: 10.1136/bmjopen-2018-028514.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sulforaphane | Small molecule | 300 mg | Oral |